Iran's impact weakens in Asia, but volatility in the Indian stock market remains high

金十2026/03/20 10:20

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Golden Ten Data reported on March 20 that the volatility of the Indian stock market has consistently been higher than other regions in Asia, indicating that investors have stronger concerns regarding India's energy dependence, high valuations, and corporate governance issues. India's volatility index remains close to its peak on March 9, which is the highest level since June 2024. For Japan and South Korea, both countries heavily reliant on fuel transported through the Strait of Hormuz, their respective volatility indicators have retreated from the highs reached due to the Iran war. The Chicago Board Options Exchange Volatility Index has also declined. This divergence suggests that, in the context of an energy crisis impacting the economy, India's risk premium is becoming increasingly stubborn. Even before the conflict, India faced challenges such as high valuations, the risk of AI technology disruption due to the lack of prominent chip manufacturers, and currency depreciation. The recent sell-off has pushed the country's stock index close to the level seen a year ago when US tariff hikes triggered market turmoil, while at the same time, governance concerns have erupted at the country's largest private bank.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

October 9 - RBC expects the performance of most European building material products to gradually improve quarter-on-quarter in Q3, but notes that geopolitical uncertainties in the US will continue to drive up cost inflation and increase market volatility. RBC anticipates that sales in Europe will remain sluggish due to heatwaves and rising mortgage rates, while a weak US housing market and the lack of a significant hurricane season will prompt roofing material companies to enter a destocking cycle. The firm is more optimistic about Germany’s Heidelberg Group (HEIG.DE), upgrading its rating to “outperform,” and points out that the company has handled the challenging quarter caused by extreme weather far better than its peers. Due to severe cost headwinds such as rising diesel and natural gas prices, RBC downgraded the ratings of US and French construction companies Knife River (KNF.N) and Saint-Gobain (SGOB.PA) from “outperform” to “market perform.” (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them solely for the ease of the reader. Reuters assumes no liability for any damages or losses that may arise from the use of automated translation functions.)

路透社•2026/10/09 07:16

3D printing materials supplier Amaero (AMRO.US) restarts US IPO, fundraising drops 60% to $20 million

Amaero (AMRO.US) on Thursday resumed its initial public offering (IPO) plans in the United States and filed new documents with the U.S. Securities and Exchange Commission (SEC), revealing a reduced number of shares to be issued.

智通财经•2026/10/09 07:11

Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.

Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.

智通财经•2026/10/09 07:09

Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.

Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.

智通财经•2026/10/09 07:08